ABSTRACT
Table 1: Pharmacological and natural inhibitors of COX (A) and LOX (B) signaling pathways that possess anti-angiogenic activity in vitro or in vivo. While the role of both NSAIDs and selective COX-2 inhibitors has been well investigated as anti-angiogenic and anti-cancer agents, less is known about their downstream prostanoid effectors. Furthermore, studies examining the role of LOX as an anti-angiogenic treatment for cancer are limited. While the majority of studies of these agents in tumor angiogenesis have been single agent studies, dual anti-angiogenic targeting has also been examined, either in combination with chemotherapy or other novel inhibitors. m, increased; o, inhibited.
